Search Results
Baxter Announces $100 Million Investment in BioPharma Solutions Halle/Westfalen, Germany Sterile Fill/Finish Manufacturing Facility
Baxter International Inc. (NYSE:BAX), a global leader in sterile medication production and delivery, today announced an approximately $100 million expansion of its sterile fill/finish manufacturing facility located in Halle/Westfalen, Germany.
Baxter Highlights New Data Indicating Sharesource Digital Health Platform for Home Dialysis May Improve Survival and Reduce Hospitalizations
Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced today new data showing kidney patients may experience a survival rate nearly two-times higher and a prolonged time to an adverse event (AE) and hospitalization when the Sharesource remote patient management digital health platform is used to help manage home automated peritoneal dialysis (APD).1
Baxter to Present at Evercore ISI 4th Annual HealthCONx Conference
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Evercore ISI 4th Annual HealthCONx Conference on Thursday, December 2, 2021. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 9:40 a.m. Eastern Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through May 21, 2022.
Baxter Reports Third-Quarter 2021 Results
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the third quarter of 2021.
Baxter and bioMérieux Announce CE Mark for NEPHROCLEAR™ CCL14 Test to Predict Persistent Severe Acute Kidney Injury
Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (EPA:BIM), a global leader in in vitro diagnostics, today announced the CE marking of the NEPHROCLEAR™ CCL14 Test. The NEPHROCLEAR™ CCL14 Test is designed to predict persistent severe acute kidney injury (PS-AKI) and can be used to support timely clinical decision-making and care pathways.
Baxter to Present at Credit Suisse 30th Annual Virtual Healthcare Conference
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Credit Suisse 30th Annual Virtual Healthcare Conference on Monday, November 8, 2021. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 8:50 a.m. Eastern Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through November 7, 2022.
Baxter Presents Critical Care Data at 34th Annual European Society of Intensive Care Medicine LIVES Congress
Baxter International Inc. (NYSE:BAX), a global leader in acute care, announced the presentation of data from three critical care studies at the 34th Annual European Society of Intensive Care Medicine (ESICM) LIVES virtual congress taking place Oct. 3 – Oct. 6, 2021.
Baxter to Host Third-Quarter 2021 Financial Results Conference Call for Investors
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its third-quarter 2021 financial results on Thursday, October 28, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/3534264 to pre-register for the call and receive the call information.
Baxter Announces U.S. Approval and Launch of Ready-To-Use Cardiovascular Medicine Norepinephrine in Premix Formulation
Baxter International Inc. (NYSE:BAX), a global leader in sterile medication production and delivery, today announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine). Norepinephrine is indicated to raise blood pressure in adult patients with severe, acute hypotension (low blood pressure).
Baxter to Acquire Hillrom, Expanding Connected Care and Medical Innovation Globally
Baxter International Inc. (NYSE:BAX), a leading global medical products company, and Hillrom (NYSE:HRC), a global medical technology leader, today announced that the companies have entered into a definitive agreement under which Baxter has agreed to acquire Hillrom for $156.00 per share in cash for a total equity value of approximately $10.5 billion and a total enterprise value of approximately $12.4 billion, including the assumption of debt.